Literature DB >> 24683196

Low invasiveness of pneumococcal serotype 11A is linked to ficolin-2 recognition of O-acetylated capsule epitopes and lectin complement pathway activation.

Allison M Brady1, Juan J Calix1, Jigui Yu1, Kimball Aaron Geno1, Gary R Cutter2, Moon H Nahm3.   

Abstract

BACKGROUND: The divergent epidemiological behavior of Streptococcus pneumoniae serotypes suggests that serotype-specific features such as capsule O-acetylation influence the propensity of a strain to cause invasive pneumococcal disease (IPD). We hypothesize that innate host factors mediate the observed negative association between IPD and the serotype 11A (ST11A) capsule O-acetyltransferase gene, wcjE.
METHODS: We evaluated the ability of ficolin-2, an initiator of the lectin complement pathway that was previously shown to bind ST11A pneumococci, to recognize and mediate complement-dependent opsonophagocytosis of different pneumococcal serotypes. We supplemented findings with an epidemiological meta-analysis comparing invasiveness of the 30 most prevalent pneumococcal serotypes.
RESULTS: Ficolin-2 bound ST11A capsule polysaccharide and other wcjE-containing pneumococcal serotypes, except ST9V and ST20B. Ficolin-2 did not bind wcjE-null serotypes, including the wcjE-null variant of ST11A, ST11E. We observed C1q-independent complement deposition and phagocytic killing of pneumococci expressing ST11A but not those expressing ST11E. Inhibition of ficolin-2 binding abrogated ST11A-associated complement deposition and phagocytosis. In children, invasiveness of ST11A was the lowest among serotypes tested in our meta-analysis, while ST9V was among the highest.
CONCLUSIONS: Ficolin-2 mediates serum protection by recognizing specific O-acetylated epitopes of pneumococcal capsule polysaccharides, exemplifying a novel host-microbe interaction that innately offers serotype-specific immunity to IPD.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Streptococcus pneumoniae; complement; ficolin-2; invasiveness; serotype 11A

Mesh:

Substances:

Year:  2014        PMID: 24683196      PMCID: PMC4215079          DOI: 10.1093/infdis/jiu195

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  50 in total

1.  Analysis of invasiveness of pneumococcal serotypes and clones circulating in Portugal before widespread use of conjugate vaccines reveals heterogeneous behavior of clones expressing the same serotype.

Authors:  Raquel Sá-Leão; Francisco Pinto; Sandra Aguiar; Sónia Nunes; João A Carriço; Nelson Frazão; Natacha Gonçalves-Sousa; José Melo-Cristino; Hermínia de Lencastre; Mário Ramirez
Journal:  J Clin Microbiol       Date:  2011-01-26       Impact factor: 5.948

2.  Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children.

Authors:  Angela B Brueggemann; Timothy E A Peto; Derrick W Crook; Jay C Butler; Karl G Kristinsson; Brian G Spratt
Journal:  J Infect Dis       Date:  2004-08-25       Impact factor: 5.226

3.  A new pneumococcal serotype, 11E, has a variably inactivated wcjE gene.

Authors:  Juan J Calix; Moon H Nahm
Journal:  J Infect Dis       Date:  2010-07-01       Impact factor: 5.226

4.  Elucidation of structural and antigenic properties of pneumococcal serotype 11A, 11B, 11C, and 11F polysaccharide capsules.

Authors:  Juan J Calix; Moon H Nahm; Edward R Zartler
Journal:  J Bacteriol       Date:  2011-07-29       Impact factor: 3.490

5.  Serum concentrations of lectin-pathway components in healthy neonates, children and adults: mannan-binding lectin (MBL), M-, L-, and H-ficolin, and MBL-associated serine protease-2 (MASP-2).

Authors:  Seraina Sallenbach; Steffen Thiel; Christoph Aebi; Margrith Otth; Susanna Bigler; Jens C Jensenius; Luregn J Schlapbach; Roland A Ammann
Journal:  Pediatr Allergy Immunol       Date:  2011-01-13       Impact factor: 6.377

Review 6.  Structural insights into the recognition properties of human ficolins.

Authors:  Virginie Garlatti; Lydie Martin; Monique Lacroix; Evelyne Gout; Gérard J Arlaud; Nicole M Thielens; Christine Gaboriaud
Journal:  J Innate Immun       Date:  2009-08-06       Impact factor: 7.349

Review 7.  Ficolins: complement-activating lectins involved in innate immunity.

Authors:  Misao Matsushita
Journal:  J Innate Immun       Date:  2009-07-24       Impact factor: 7.349

8.  Comparative structural and molecular characterization of Streptococcus pneumoniae capsular polysaccharide serogroup 10.

Authors:  Jinghua Yang; Moon H Nahm; C Allen Bush; John O Cisar
Journal:  J Biol Chem       Date:  2011-08-22       Impact factor: 5.157

9.  Death or survival from invasive pneumococcal disease in Scotland: associations with serogroups and multilocus sequence types.

Authors:  Donald Inverarity; Karen Lamb; Mathew Diggle; Chris Robertson; David Greenhalgh; Tim J Mitchell; Andrew Smith; Johanna M C Jefferies; Stuart C Clarke; Jim McMenamin; Giles F S Edwards
Journal:  J Med Microbiol       Date:  2011-03-10       Impact factor: 2.472

10.  Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study.

Authors:  Zitta B Harboe; Reimar W Thomsen; Anders Riis; Palle Valentiner-Branth; Jens Jørgen Christensen; Lotte Lambertsen; Karen A Krogfelt; Helle B Konradsen; Thomas L Benfield
Journal:  PLoS Med       Date:  2009-05-26       Impact factor: 11.069

View more
  25 in total

1.  The Pneumococcal Serotype 15C Capsule Is Partially O-Acetylated and Allows for Limited Evasion of 23-Valent Pneumococcal Polysaccharide Vaccine-Elicited Anti-Serotype 15B Antibodies.

Authors:  Brady L Spencer; Anukul T Shenoy; Carlos J Orihuela; Moon H Nahm
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

2.  WciG O-Acetyltransferase Functionality Differentiates Pneumococcal Serotypes 35C and 42.

Authors:  K Aaron Geno; C Allen Bush; Mengnan Wang; Cheng Jin; Moon H Nahm; Jinghua Yang
Journal:  J Clin Microbiol       Date:  2017-06-28       Impact factor: 5.948

3.  Rapid and efficient purification of ficolin-2 using a disposable CELLine bioreactor.

Authors:  K Aaron Geno; Brady L Spencer; Moon H Nahm
Journal:  J Immunol Methods       Date:  2015-05-30       Impact factor: 2.303

4.  Discovery of Novel Pneumococcal Serotype 35D, a Natural WciG-Deficient Variant of Serotype 35B.

Authors:  K Aaron Geno; Jamil S Saad; Moon H Nahm
Journal:  J Clin Microbiol       Date:  2017-02-15       Impact factor: 5.948

Review 5.  Pneumococcal Capsules and Their Types: Past, Present, and Future.

Authors:  K Aaron Geno; Gwendolyn L Gilbert; Joon Young Song; Ian C Skovsted; Keith P Klugman; Christopher Jones; Helle B Konradsen; Moon H Nahm
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

6.  Position of O-Acetylation within the Capsular Repeat Unit Impacts the Biological Properties of Pneumococcal Serotypes 33A and 33F.

Authors:  Brady L Spencer; Jamil S Saad; Anukul T Shenoy; Carlos J Orihuela; Moon H Nahm
Journal:  Infect Immun       Date:  2017-06-20       Impact factor: 3.441

7.  Interplay of Carbohydrate and Carrier in Antibacterial Glycoconjugate Vaccines.

Authors:  Tyler D Moeller; Kevin B Weyant; Matthew P DeLisa
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

8.  Commercially available complement component-depleted sera are unexpectedly codepleted of ficolin-2.

Authors:  Allison M Brady; K Aaron Geno; Alex G Dalecki; Xiaogang Cheng; Moon H Nahm
Journal:  Clin Vaccine Immunol       Date:  2014-07-16

9.  Monoclonal Antibodies to Shigella Lipopolysaccharide Are Useful for Vaccine Production.

Authors:  Jisheng Lin; Mark A Smith; William H Benjamin; Robert W Kaminski; Heather Wenzel; Moon H Nahm
Journal:  Clin Vaccine Immunol       Date:  2016-08-05

10.  Single-Nucleotide Polymorphisms within the cps Loci: Another Potential Source of Clinically Important Genetic Variation for Streptococcus pneumoniae?

Authors:  Jeremy S Brown
Journal:  Infect Immun       Date:  2021-08-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.